Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Alnylam nets $30.2mm with IPO

Executive Summary

Alnylam Pharmaceuticals, a company developing therapeutics based on RNA interference (RNAi), sold 5.75mm common shares (including the overallotment) priced at $6 each in its initial public offering, raising net proceeds of $30.2mm. The company originally filed in February, hoping to bring in up to $86.25mm.
Deal Industry
  • Pharmaceuticals
  • Pharmaceuticals
    • Drug Delivery
      • Site Specific
  • Biotechnology
    • Drug Discovery Tools
      • Genomics-Proteomics
Deal Status
  • Final
Deal Type
  • Financing
    • IPO

Related Companies